Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements

About this update from Tarsus Pharmaceuticals, Inc.

Launched XDEMVY ® (lotilaner ophthalmic solution) 0.25%, for the treatment of Demodex blepharitis and generated fourth quarter net product sales of $13.1 million , and $14.7 million in the first four months since launch Delivered more than 17,400 bottles of XDEMVY to patients Continued pipeline execution – reported positive proof-of-concept results across entire clinical portfolio Management to host conference call today, February 27, 2024 , at 5 a.m. PT / 8 a.m. ET IRVINE, Calif. , Feb. 27, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the fourth quarter and full-year ended December 31, 2023 , and recent business achievements. “Tarsus is establishing the next category in eye care and these strong results reflect our team’s ability to execute and deliver on our mission to bring revolutionary new medicines to patients,” said Bobak Azamian , M.D., Ph.D., Chief Executive Officer and Chairman of Tarsus. “2024 is off to a great start, driven by the approval, launch and rapid uptake of XDEMVY, and the momentum we’ve already established is setting the tone for what we expect to be an impactful year ahead.” Recent Business Highlights and Corporate Update Generated strong prescription and sales growth of XDEMVY in 2023 enabled by execution of key commercial initiatives, including deployment of an experienced sales force targeting 15,000 Eye Care Providers (ECPs) representing >80% of all eye care prescriptions, and high-impact disease education leading to ECP adoption. Additionally: Reported $14.7 million in XDEMVY net product sales Delivered more than 17,400 bottles of XDEMVY to patients Approximately 6,000 ECPs have started patients on XDEMVY with more than 50% of ECPs prescribing XDEMVY to multiple patients as of February 23, 2024 Six manuscripts published in peer-reviewed journals in 2023 including: Saturn-1, one-year extension data highlighting the safety and durable response of XDEMVY Two independent meta-analyses validating efficacy, safety and impact of our study results Continued to advance our pipeline with the recent reporting of positive topline data: Ersa Phase 2a clinical trial evaluating TP-03 for the treatment of Meibomian Gland Disease in patients with Demodex mites Carpo Phase 2a clinical trial evaluating TP-05 for the prevention of Lyme disease Additionally, today we are announcing positive topline results from the Phase 2a Galatea trial evaluating TP-04 for the treatment of Papulopustular Rosacea (PPR), which demonstrate: Statistically significant improvements (p

View stock analysis, news, and events for Tarsus Pharmaceuticals, Inc.